MCID: LPD008
MIFTS: 62

Lipid Metabolism Disorder

Categories: Metabolic diseases, Rare diseases

Aliases & Classifications for Lipid Metabolism Disorder

MalaCards integrated aliases for Lipid Metabolism Disorder:

Name: Lipid Metabolism Disorder 12 15
Dyslipidemia 12 54 15
Disorder of Fatty Acid Metabolism 29 71
Abnormality of Lipid Metabolism 29 6
Lipid Metabolism Disorders 42 71
Lipid Metabolism, Inborn Errors 44
Fatty Acid Metabolism Disorder 12
Disorder of Lipid Metabolism 58
Dyslipidemias 71

Classifications:

Orphanet: 58  
Inborn errors of metabolism


External Ids:

Disease Ontology 12 DOID:3146
MeSH 44 D008052
ICD10 32 E71.3
UMLS via Orphanet 72 C0154251
Orphanet 58 ORPHA309005
UMLS 71 C0023772 C0154251 C0242339 more

Summaries for Lipid Metabolism Disorder

MedlinePlus : 42 Metabolism is the process your body uses to make energy from the food you eat. Food is made up of proteins, carbohydrates, and fats. Chemicals in your digestive system (enzymes) break the food parts down into sugars and acids, your body's fuel. Your body can use this fuel right away, or it can store the energy in your body tissues. If you have a metabolic disorder, something goes wrong with this process. Lipid metabolism disorders, such as Gaucher disease and Tay-Sachs disease, involve lipids. Lipids are fats or fat-like substances. They include oils, fatty acids, waxes, and cholesterol. If you have one of these disorders, you may not have enough enzymes to break down lipids. Or the enzymes may not work properly and your body can't convert the fats into energy. They cause a harmful amount of lipids to build up in your body. Over time, that can damage your cells and tissues, especially in the brain, peripheral nervous system, liver, spleen, and bone marrow. Many of these disorders can be very serious, or sometimes even fatal. These disorders are inherited. Newborn babies get screened for some of them, using blood tests. If there is a family history of one of these disorders, parents can get genetic testing to see whether they carry the gene. Other genetic tests can tell whether the fetus has the disorder or carries the gene for the disorder. Enzyme replacement therapies can help with a few of these disorders. For others, there is no treatment. Medicines, blood transfusions, and other procedures may help with complications.

MalaCards based summary : Lipid Metabolism Disorder, also known as dyslipidemia, is related to hypobetalipoproteinemia, familial, 1 and lipodystrophy, familial partial, type 2. An important gene associated with Lipid Metabolism Disorder is FADS1 (Fatty Acid Desaturase 1), and among its related pathways/superpathways are Metabolism and Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha). The drugs Tocopherol and Cilostazol have been mentioned in the context of this disorder. Affiliated tissues include endothelial, ovary and kidney, and related phenotypes are Decreased free cholesterol and Decreased LDL uptake

Disease Ontology : 12 An inherited metabolic disorder that involves the creation and degradation of lipids.

Wikipedia : 74 Lipid metabolism is the synthesis and degradation of lipids in cells, involving the breakdown or storage... more...

Related Diseases for Lipid Metabolism Disorder

Diseases related to Lipid Metabolism Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 658)
# Related Disease Score Top Affiliating Genes
1 hypobetalipoproteinemia, familial, 1 32.6 APOE APOC3 APOB APOA5 APOA1
2 lipodystrophy, familial partial, type 2 32.3 PPARG PPARA LEP INS ADIPOQ
3 hypolipoproteinemia 32.1 LPL CETP APOE APOC3 APOB APOA1
4 hyperlipoproteinemia, type iii 32.1 LPL LIPC HMGCR CETP APOE APOB
5 hypercholesterolemia, familial, 1 32.0 LPL LIPC INS HMGCR CRP CETP
6 hypertriglyceridemia, familial 32.0 SERPINE1 LPL LIPC INS CETP APOE
7 abdominal obesity-metabolic syndrome 1 31.9 SERPINE1 RETN PPARG PPARA LPL LEP
8 prediabetes syndrome 31.9 SERPINE1 RETN PPARG LEP INS HNF4A
9 hyperglycemia 31.6 SERPINE1 RETN PPARG LPL LEP INS
10 liver disease 31.5 RETN PPARA LEP INS ADIPOQ
11 hyperinsulinism 31.4 SERPINE1 RETN PPARG PPARA LPL LEP
12 mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome 31.4 PPARG LEP INS ADIPOQ
13 polycystic ovary syndrome 31.4 RETN PPARG LEP INS ADIPOQ
14 arteries, anomalies of 31.3 SERPINE1 LEP INS CRP APOE APOB
15 end stage renal disease 31.2 LEP INS CRP APOB ADIPOQ ACE
16 atherosclerosis susceptibility 31.2 SERPINE1 RETN PPARG PPARA LPL LIPC
17 familial hypercholesterolemia 31.2 SERPINE1 LPL LIPC INS HMGCR CRP
18 homozygous familial hypercholesterolemia 31.1 LIPC HMGCR APOE APOB APOA1
19 fatty liver disease 31.1 SERPINE1 RETN PPARG PPARA LEP INS
20 peripheral vascular disease 31.0 SERPINE1 HMGCR CRP CETP APOB APOA1
21 body mass index quantitative trait locus 11 31.0 SERPINE1 RETN PPARG PPARA LPL LIPC
22 gestational diabetes 31.0 RETN PPARG LEP INS HNF4A CRP
23 pre-eclampsia 31.0 SERPINE1 LEP INS CRP ADIPOQ ACE
24 cerebrovascular disease 31.0 SERPINE1 RETN LPL LEP INS CRP
25 hyperandrogenism 31.0 PPARG INS ADIPOQ
26 stroke, ischemic 31.0 SERPINE1 HMGCR CRP APOE APOB ACE
27 sleep apnea 31.0 SERPINE1 RETN LEP INS CRP APOE
28 kidney disease 30.9 SERPINE1 RETN PPARG LEP INS HMGCR
29 vascular disease 30.9 SERPINE1 RETN PPARG LPL LIPC LEP
30 type 1 diabetes mellitus 30.9 RETN LEP INS HNF4A CRP CETP
31 hyperlipidemia, familial combined, 3 30.9 PPARA LPL LIPC INS HMGCR CETP
32 uremia 30.9 RETN LPL LEP INS CRP APOC3
33 hyperthyroidism 30.9 RETN LEP INS CRP
34 peripheral artery disease 30.9 RETN LEP CRP APOE APOB APOA1
35 arteriosclerosis 30.9 SERPINE1 PPARG PPARA INS HMGCR CRP
36 lipoprotein quantitative trait locus 30.9 SERPINE1 RETN PPARG PPARA LPL LIPC
37 acute pancreatitis 30.8 RETN LPL INS CRP
38 sitosterolemia 30.8 HMGCR APOB APOA1
39 heart disease 30.8 SERPINE1 RETN PPARG PPARA LPL LEP
40 anovulation 30.8 LEP INS CRP
41 acute myocardial infarction 30.8 SERPINE1 HMGCR CRP APOB APOA1 ACE
42 homocysteinemia 30.8 SERPINE1 CRP APOE
43 diabetic neuropathy 30.7 LEP INS ACE
44 hypoalphalipoproteinemia 30.7 LIPC APOA1
45 chlamydia pneumonia 30.7 PPARG CRP APOE
46 non-alcoholic fatty liver disease 30.7 SERPINE1 RETN PPARG PPARA LPL LEP
47 neuroretinitis 30.7 CRP ACE
48 leptin deficiency or dysfunction 30.7 RETN PPARG PPARA LPL LEP INS
49 aortic aneurysm, familial abdominal, 1 30.7 SERPINE1 CRP CETP APOE ACE
50 defective apolipoprotein b-100 30.7 HMGCR APOE APOB

Comorbidity relations with Lipid Metabolism Disorder via Phenotypic Disease Network (PDN):


Hypertension, Essential Intermediate Coronary Syndrome

Graphical network of the top 20 diseases related to Lipid Metabolism Disorder:



Diseases related to Lipid Metabolism Disorder

Symptoms & Phenotypes for Lipid Metabolism Disorder

GenomeRNAi Phenotypes related to Lipid Metabolism Disorder according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased free cholesterol GR00340-A-2 8.65 LIPC
2 Decreased LDL uptake GR00340-A-1 8.32 LPL

MGI Mouse Phenotypes related to Lipid Metabolism Disorder:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.32 ACE ADIPOQ APOA1 APOA5 APOB APOE
2 cardiovascular system MP:0005385 10.29 ACE ADIPOQ APOA1 APOB APOE CRP
3 cellular MP:0005384 10.23 ADIPOQ APOA1 APOB APOE FADS1 HMGCR
4 growth/size/body region MP:0005378 10.22 ACE ADIPOQ APOB APOE FADS1 HMGCR
5 adipose tissue MP:0005375 10.19 ACE ADIPOQ APOE INS LEP LPL
6 endocrine/exocrine gland MP:0005379 10.13 ACE ADIPOQ APOA1 APOE FADS1 HNF4A
7 immune system MP:0005387 10.1 ACE ADIPOQ APOB APOE CRP FADS1
8 liver/biliary system MP:0005370 10 ACE ADIPOQ APOA1 APOB APOE HMGCR
9 integument MP:0010771 9.91 ADIPOQ APOA1 APOE INS LEP LPL
10 muscle MP:0005369 9.56 ADIPOQ APOB APOE INS LEP LPL
11 renal/urinary system MP:0005367 9.32 ACE ADIPOQ APOE FADS1 HNF4A INS

Drugs & Therapeutics for Lipid Metabolism Disorder

Drugs for Lipid Metabolism Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 327)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tocopherol Approved, Investigational Phase 4 1406-66-2
2
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
3
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
4
Bilberry Approved, Experimental Phase 4
5
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
6
Nateglinide Approved, Investigational Phase 4 105816-04-4 60026
7
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
8
Pravastatin Approved Phase 4 81093-37-0 54687
9
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
10
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
11
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
12
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
13
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
14
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030
15
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
16
Bezafibrate Approved, Investigational Phase 4 41859-67-0 39042
17
Zidovudine Approved Phase 4 30516-87-1 35370
18
Levoleucovorin Approved, Investigational Phase 4 68538-85-2 149436
19
deoxycholic acid Approved Phase 4 83-44-3 222528
20
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
21
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
22
Losartan Approved Phase 4 114798-26-4 3961
23
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
24
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
25
Nevirapine Approved Phase 4 129618-40-2 4463
26 Orange Approved Phase 4
27
Ciprofibrate Approved, Investigational Phase 4 52214-84-3 2763
28
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
29
Lopinavir Approved Phase 4 192725-17-0 92727
30
Calcium polycarbophil Approved Phase 4 126040-58-2
31
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
32
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
33
Pitavastatin Approved Phase 4 147511-69-1, 147526-32-7 6366718 5282452
34 Coconut Approved Phase 4
35
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
36
Empagliflozin Approved Phase 4 864070-44-0
37
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
38
Fenofibrate Approved Phase 4 49562-28-9 3339
39
Evolocumab Approved Phase 4 1256937-27-5
40 Fenofibric acid Approved Phase 4 42017-89-0
41
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
42
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
43
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
44
Choline Approved, Nutraceutical Phase 4 62-49-7 305
45
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
46
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
47 Tocotrienol Investigational Phase 4 6829-55-6
48
Candesartan Experimental Phase 4 139481-59-7 2541
49
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
50
Cobalamin Experimental Phase 4 13408-78-1 6857388

Interventional clinical trials:

(show top 50) (show all 962)
# Name Status NCT ID Phase Drugs
1 An Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate Simvastatin 20 mg Plus Omacor 4g Compared to Simvastatin 20 mg Plus Placebo in Subjects With Mixed Dyslipidemia Unknown status NCT00678743 Phase 4 Omacor + simvastatin
2 Effects of Nicotinic Acid Plus Simvastatin Versus Simvastatin Alone on Carotid and Femoral Intima-Media Thickness in Patients With Peripheral Artery Disease (NASCIT)-A Randomized Controlled Trial Unknown status NCT00712049 Phase 4 simvastatin;Nicotinic Acid
3 Effects of Dapagliflozin on Hyperlipidemia, Glycemic Control and Insulin Resistance in Type 2 Diabetic Patients (DAPHNIS Study) Unknown status NCT02577159 Phase 4 Dapagliflozin
4 Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients Unknown status NCT02933788 Phase 4 Cilostazol;Acetylsalicylic acid
5 Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia by Aripiprazole Add-on Therapy in the Treatment of Schizophrenia and Bipolar Disorder: An Open-Label Trial Unknown status NCT00541554 Phase 4 Abilify (aripiprazole)
6 Study on the Efficacy aNd Safety of Jinlida Granules in Patients With Inadequately cOntrolled tYpe-2 Diabetes and dysLIpidemia Under liFe Style Intervention (ENJOY LIFE Study) Unknown status NCT02035644 Phase 4 Jinlida granules;placebo granules
7 A Multi-center, Randomized, Parallel Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Triple Therapy of Telmisartan/Amlodipine/Rosuvastatin in Patients With Dyslipidemia and Hypertension Unknown status NCT03860220 Phase 4 NEWSTATIN TS;CADUET
8 Comparison of High-Dose Rosuvastatin Versus Low Statin Dose Plus Fenofibrate Versus Low Statin Dose Plus Niacin in the Treatment of Mixed Hyperlipidemia Unknown status NCT01010516 Phase 4 High-dose rosuvastatin;Statin plus fenofibrate;Statin plus niacin ER/laropiprant
9 An Open-label, Randomized, Multi-centre, Phase IVb, Parallel Study Group to Compare the Efficacy and Safety of 5 mg and 10 mg Rosuvastatin Unknown status NCT01613729 Phase 4 Rosuvastatin 5 mg;Rosuvastatin 10 mg
10 An Randomized Open Label Trial on the Impact of 24 Weeks of Atorvastatin Therapy on Liver Fat Content and Abdominal Fat Content in Patients With Type 2 Diabetes Combined With High LDL-C and Non-alcoholic Fatty Liver Disease Unknown status NCT01720719 Phase 4 atorvastatin;Vitamin E
11 Long-term Effect of Nasal Continuous Positive Airway Pressure on Lipid Profile in Patients With Dyslipidaemia and Mild-moderate Obstructive Sleep Apnea Unknown status NCT02557412 Phase 4
12 Ezetimibe Reverse Cholesterol Transport (RCT) Pilot Study Completed NCT00701727 Phase 4 ezetimibe;Placebo
13 A Multi-center, Open-label, Randomized, Active-control, Parallel-group Designed Study to Compare Effects of Nateglinide and Acarbose on Postprandial Status in Chinese Drug-naive Type 2 Diabetes Mellitus Patients Completed NCT00928889 Phase 4 Nateglinide 120 mg;Acarbose 50 mg
14 A 12-Week, Double-Blind, Randomized, Placebo-Controlled Study to Assess the LDL Cholesterol Lowering and Anti-Hyperglycemic Efficacy of Welchol® (Colesevelam) in Subjects With Impaired Fasting Glucose Who Are Taking Niaspan® (Niacin) for Dyslipidemia Completed NCT01239004 Phase 4 Placebo;Colesevelam
15 SLIM: Combined Effects of Slo-Niacin and Atorvastatin on Lipoproteins and Inflammatory Markers Completed NCT00194402 Phase 4 Slo-Niacin, atorvastatin
16 Efficacy of a Computerised Physician Reminder System to Control Cardiovascular Risk Factors in HIV-infected Patients Receiving Antiretroviral Therapy: A Nested Randomised Controlled Cluster Trial Within the Swiss HIV Cohort Study Completed NCT00264394 Phase 4
17 Efficacy and Safety of Fluvastatin 80 mg or Valsartan 160 mg and Their Combination in Dyslipidemic Patients With Arterial Hypertension and Endothelial Dysfunction Completed NCT00171327 Phase 4 valsartan, fluvastatin
18 Evaluation of the Efficacy and Safety of Rosuvastatin 5 mg Versus Pravastatin 40 mg and Atorvastatin 10 mg in Subjects With Type IIa and IIb Hypercholesterolaemia Completed NCT00631189 Phase 4 Rosuvastatin;Pravastatin;Atorvastatin
19 Yoga for the Management of HIV-Metabolic Syndromes Completed NCT00627380 Phase 4
20 Neointimal Coverage After Implantation of Biolimus Eluting Stent With Biodegradable Polymer: Optical Coherence Tomographic Assessment According to the Treatment of Dyslipidemia and Hypertension and the Types of Implanted Drug-eluting Stents Completed NCT01502904 Phase 4 pravastatin 20mg/day after DES implantation;pitavastatin 2mg/day after DES implantation;Non-ARB /day after DES implantation;Eposartan 600mg/day after DES implantation
21 A 12-week, Multicenter, Double-blind, Double-dummy, Randomized, Active-controlled, Parallel-group Study to Assess the Efficacy and Safety of Fluvastatin Sodium Extended Release Tablets 80 mg Once Daily Compared to Fluvastatin Sodium Immediate Release Capsules 40 mg Twice Daily (BID) in Chinese Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia at Moderate or High Cardiovascular Risk Who Did Not Achieve Their Lipid Goals When Treated With Fluvastatin Sodium Immediate Release Capsules 40 mg QD Completed NCT01551173 Phase 4 Fluvastatin sodium
22 Open Label Study Evaluating The Use Of Combination Therapy Of Ezetimibe And Statins In Patients With Dyslipidemia In Colombia Completed NCT00651963 Phase 4 ezetimibe
23 Serial EValuation of multiplE Coronary Artery Diseases by an Optical Coherence Tomography; Assessment of the Changes of de Novo Lesions and Comparisons of Neointimal Coverage Between Xience Prime® Versus Cypher SelectTM Stents; SEVEN-Xience Study Completed NCT01856374 Phase 4 Pravastatin 20mg;Atorvastatin 40mg
24 The Effect of Fibrate Therapy in Two Patients With Neutral Lipid Storage Disease With Myopathy (NLSDM) Completed NCT01527318 Phase 4 Fibrate treatment
25 Assessment of the Efficacy and Tolerability of Two Formulations of Atorvastatin In Korean Adult With Hypercholesterolemia : A Multicenter, Prospective, Open-Label, Randomized, Trial Completed NCT01285544 Phase 4 Atorvastatin (Lipinon);Atorvastatin (Lipitor)
26 A Multi-center, Randomized, Double-blinded Equivalence Clinical Trial to Evaluate Efficacy and Safety of LipiLou 20 mg Versus Lipitor 20 mg in Hypercholesterolemic Patients With Higher Risk Cardiovascular Disease in Korea Completed NCT01029522 Phase 4 Atorvastatin (Lipilou);Atorvastatin (Lipitor)
27 Fat Reduction in the Submental Area - a Sequential Treatment Approach With CoolMini and KYBELLA® Completed NCT03510598 Phase 4 Kybella 20 MG in 2 ML Injection
28 Effect of Anthocyanins on Metabolic Profiles in Subjects With Pre-diabetes: A Randomized, Double-blind, Placebo-controlled Study Completed NCT02689765 Phase 4
29 Regulation of Lipoprotein Kinetics by Atorvastatin and Fenofibrate With the Metabolic Syndrome Completed NCT00632840 Phase 4 Atorvastatin and fenofibrate
30 Effect of PPAR-Delta Agonist on Lipoprotein Kinetics in Metabolic Syndrome Completed NCT00841217 Phase 4 GW501516;placebo pill
31 Open-label, Randomized, Single Center, Paralleled Clinical Study to Evaluate Adherence Improvement Fixed-dose Combination of Olostar Tab. in Patients With Hypertension and Dyslipidemia Completed NCT04061824 Phase 4 Olostar Tab (olmesartan/rosuvastatin FDC(fixed dose combination));Two separated drugs(ARB(Angiotensin Ⅱ receptor blocker) and statin)
32 Acute Effects of Sodium-glucose Cotransporter-2 Inhibition on Renal Oxygenation and Autonomic Function in Type 1 Diabetes Completed NCT04193566 Phase 4 Forxiga
33 A Multicenter, Eight-Week Treatment, Single-Step Titration Open-Label Study Assessing The Percentage Of Korean Dyslipidemic Patients Achieving LDL Cholesterol Target With Atorvastatin Starting Doses Of 10 MG, 20 MG, And 40 MG. Completed NCT00540293 Phase 4 Atorvastatin
34 An Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Statin-fenofibrate Combination Therapy in Dyslipidemic Chinese Patients Completed NCT01462877 Phase 4 fenofibrate
35 Effect On Serum Cholesterol Of Dairy Products With Addition Of Esterified Phytosterols In Chilean Subjects With Hypercholesterolemia Completed NCT02644109 Phase 4
36 Statins and Noncardiovascular Endpoints Completed NCT00330980 Phase 4 40 mg Pravastatin (Pravachol);20 mg Simvastatin;Placebo
37 A Multicenter, Eight-Week Treatment, Single-Step Titration, Open-Label Study Assessing The Percentage Of Dyslipidemic Patients Achieving LDL Cholesterol Target With Atorvastatin Starting Doses Of 10 Mg, 20 Mg, And 40 Mg Completed NCT00647543 Phase 4 Atorvastatin;Atorvastatin;Atorvastatin
38 A Multicenter, Eight-Week Treatment, Single Step Titration, Open-Label Study Assessing The Percentage Of Subjects Achieving Low Density Lipoprotein Cholesterol Target With Atorvastatin Starting Doses Of 10 Mg, 20 Mg, 40 Mg, And 80 Mg (Latin American Atorvastatin ATGOAL Study) Completed NCT00645151 Phase 4 Atorvastatin;Atorvastatin;Atorvastatin
39 A Multicenter, Open-Label Extension Study Of High-Risk Hyperlipidemic Patients Treated With An Atorvastatin Starting Dose Adapted To Their Baseline LDL-C Level Completed NCT00644709 Phase 4 Atorvastatin
40 A Multicenter, Twelve-Week Treatment, Single-Step Titration, Open-Label Study Assessing The Percentage Of Dyslipidemic High-Risk Patients Achieving LDL Cholesterol Targets With Atorvastatin Starting Doses Of 10 Mg, 20 Mg And 40 Mg. Completed NCT00644670 Phase 4 Atorvastatin;Atorvastatin
41 Comparison Between XueZhiKang and Simvastatin on Fatigue: a Single-center, Randomized Clinical Trial Completed NCT01686451 Phase 4 XueZhiKang;simvastatin
42 A RANDOMIZED, DOUBLE-BLIND, ACTIVE CONTROLLED, PARALLEL GROUP STUDY OF PITAVASTATIN 4 MG VS. PRAVASTATIN 40 MG IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA Completed NCT01256476 Phase 4 pitavastatin;pravastatin
43 A Multicenter, Pragmatic Randomized, Double-blind, Placebo-controlled Trial of Xuezhikang Capsule for Treating Dyslipidemia: a Postmarketing Study Completed NCT02057302 Phase 4 Xuezhikang capsule
44 Metformin for Treatment of Antipsychotic-induced Dyslipidemia: a Randomized, Double-blind Study Completed NCT01778244 Phase 4 metformin
45 A 12-Week, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study Comparing Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV-Infected Subjects With Dyslipidemia, Followed by a 40-Week Safety Extension Study Completed NCT01301066 Phase 4 Pitavastatin;Pravastatin
46 A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy Completed NCT02642159 Phase 4 Alirocumab;Statins;Ezetimibe;Fenofibrate;Nicotinic acid;Omega-3 fatty acids;Antihyperglycemic Drug
47 Efficacy and Safety of Extended Release Niacin-Fenofibrate Combination and Monotherapy for the Treatment of Atherogenic Dyslipidemia in Obese Females Completed NCT03615534 Phase 4 Fenofibrate
48 Efficacy of Atorvastatin Versus Rosuvastatin on LV Function and Inflammatory Biomarkers in Type 2 Diabetic Patients With Dyslipidemia Completed NCT03784703 Phase 4 Atorvastatin 40 Mg Oral Tablet;Rosuvastatin 10 Mg Oral Tablet
49 Prospective, Randomised, Crossover, Double-Blind, Placebo-Controlled Trial To Assess The Lipid-Lowering Effect Of Adding Tenofovir/Emtricitabine Co-Formulation Vs Placebo To Hiv-1-Infected Subjects With Dyslipidemia And Sustained Viral Load Suppression Under Monotherapy With Ritonavir-Boosted Protease Inhibitors Completed NCT01458977 Phase 4 Truvada® (300 mg tenofovir disoproxil fumarato/200 mg emtricitabine);Placebo
50 Efavirenz to Nevirapine Switch in HIV-1 Infected Patients With Severe Dyslipidemia: A Randomized Controlled Study Completed NCT00405171 Phase 4 Nevirapine

Search NIH Clinical Center for Lipid Metabolism Disorder

Cochrane evidence based reviews: lipid metabolism, inborn errors

Genetic Tests for Lipid Metabolism Disorder

Genetic tests related to Lipid Metabolism Disorder:

# Genetic test Affiliating Genes
1 Disorder of Fatty Acid Metabolism 29
2 Abnormality of Lipid Metabolism 29

Anatomical Context for Lipid Metabolism Disorder

MalaCards organs/tissues related to Lipid Metabolism Disorder:

40
Endothelial, Ovary, Kidney, Liver, Thyroid, Heart, Adipocyte

Publications for Lipid Metabolism Disorder

Articles related to Lipid Metabolism Disorder:

(show top 50) (show all 28647)
# Title Authors PMID Year
1
Comparison of pleiotropic effects of statins vs fibrates on laboratory parameters in patients with dyslipidemia: A retrospective cohort study. 61 42
33327270 2020
2
Effectiveness and safety of Hwangryunhaedok-Tang (Huang-Lian-Jie-Du-Tang, Oren-Gedoku-to) for dyslipidemia: A protocol for a PRISMA-compliant systematic review and meta-analysis. 61 42
33371067 2020
3
Prevalence and management of hypercholesterolemia in France, the Esteban observational study. 42
33327276 2020
4
Targeting dyslipidemia in the metabolic syndrome: an update. 54 61
19485929 2010
5
Insulin resistance is associated with C-reactive protein independent of abdominal obesity in nondiabetic Taiwanese. 61 54
20004425 2010
6
Insulin resistance, dyslipidemia, and metabolic syndrome in women with polycystic ovary syndrome. 61 54
20199774 2010
7
Association of low testosterone with metabolic syndrome and its components in middle-aged Japanese men. 61 54
20339372 2010
8
Ala54Thr polymorphism of fatty acid-binding protein 2 gene and fasting blood lipids: a meta-analysis. 54 61
20047744 2010
9
Nuclear receptors as drug targets in cholestasis and drug-induced hepatotoxicity. 54 61
20388526 2010
10
A novel germline mutation in peroxisome proliferator-activated receptor gamma gene associated with large intestine polyp formation and dyslipidemia. 61 54
20123124 2010
11
Fenofibrate antagonizes Chk2 activation by inducing Wip1 expression: implications for cell proliferation and tumorigenesis. 54 61
20226795 2010
12
Is there a link between inflammation and abnormal lipoprotein profile in Sjögren's syndrome? 61 54
20378384 2010
13
Osteoprotegerin in relation to type 2 diabetes mellitus and the metabolic syndrome in postmenopausal women. 61 54
19922962 2010
14
The effect of PPAR-alpha agonism on apolipoprotein metabolism in humans. 61 54
20005515 2010
15
Cardiovascular and metabolic risk profile and acylation-stimulating protein levels in children with Prader-Willi syndrome and effects of growth hormone treatment. 54 61
20173020 2010
16
Liver X receptor activation promotes macrophage-to-feces reverse cholesterol transport in a dyslipidemic hamster model. 54 61
19965597 2010
17
Peroxisome proliferator-activated receptor-delta genotype influences metabolic phenotype and may influence lipid response to statin therapy in humans: a genetics of diabetes audit and research Tayside study. 54 61
20200337 2010
18
Hormone and pharmaceutical regulation of ASP production in 3T3-L1 adipocytes. 61 54
20069551 2010
19
[Statins in the management of acute coronary syndrome]. 61 54
20387563 2010
20
Concordance of two multiple analytical approaches demonstrate that interaction between BMI and ADIPOQ haplotypes is a determinant of LDL cholesterol in a general French population. 54 61
20186155 2010
21
Type 2 diabetes mellitus is characterized by reduced postprandial adiponectin response: a possible link with diabetic postprandial dyslipidemia. 54 61
19922965 2010
22
Interrelationships of Factor VII activity and plasma leptin with insulin resistance in coronary heart disease. 54 61
19781705 2010
23
Pharmacologic inhibition of phospholipid transfer protein activity reduces apolipoprotein-B secretion from hepatocytes. 61 54
19933370 2010
24
Bone mineral density and atherosclerosis: the Multi-Ethnic Study of Atherosclerosis, Abdominal Aortic Calcium Study. 61 54
19819456 2010
25
Metabolism and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in humans. 54 61
20016053 2010
26
Bezafibrate induces myotoxicity in human rhabdomyosarcoma cells via peroxisome proliferator-activated receptor alpha signaling. 61 54
19683050 2010
27
[Effects of PPARgamma agonist on dyslipidemia and atherosclerosis]. 61 54
20158099 2010
28
Genetic association and interaction analysis of USF1 and APOA5 on lipid levels and atherosclerosis. 54 61
19910639 2010
29
Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia. 54 61
20104931 2010
30
Development of apolipoprotein B antisense molecules as a therapy for hyperlipidemia. 54 61
20425272 2010
31
Serum fibroblast growth factor 21 levels in gestational diabetes mellitus in relation to insulin resistance and dyslipidemia. 54 61
19699495 2010
32
[Prevalence of cardiovascular disease in uraemia and relevance of cardiovascular risk factors]. 54 61
20514101 2010
33
The common biological basis for common complex diseases: evidence from lipoprotein lipase gene. 54 61
19639021 2010
34
Effects of weight loss on lipid transfer proteins in morbidly obese women. 61 54
19789902 2009
35
[A case-control study on risk factors of type 2 diabetes mellitus related chronic complications in Baoding city]. 61 54
20193318 2009
36
Decrease in FASN expression in adipose tissue of hypertensive individuals. 54 61
19851294 2009
37
Expression of human apoAII in transgenic rabbits leads to dyslipidemia: a new model for combined hyperlipidemia. 61 54
19778946 2009
38
Decreased PPAR gamma expression compromises perigonadal-specific fat deposition and insulin sensitivity. 54 61
19749155 2009
39
Serum retinol-binding protein 4 correlates with obesity, insulin resistance, and dyslipidemia in HIV-infected subjects receiving highly active antiretroviral therapy. 54 61
19501863 2009
40
Deletion of protein tyrosine phosphatase 1b improves peripheral insulin resistance and vascular function in obese, leptin-resistant mice via reduced oxidant tone. 54 61
19797171 2009
41
Increase in gamma-glutamyltransferase level and development of established cardiovascular risk factors and diabetes in Japanese adults. 54 61
19419267 2009
42
ACP1 genotype, glutathione reductase activity, and riboflavin uptake affect cardiovascular risk in the obese. 54 61
19570551 2009
43
Adiponectin is associated with cardiovascular disease in male renal transplant recipients: baseline results from the LANDMARK 2 study. 54 61
19821969 2009
44
[Secondary dyslipidaemia after oral contraceptives]. 61 54
19947236 2009
45
Splenomegaly with sea-blue histiocytosis, dyslipidemia, and nephropathy in a patient with lecithin-cholesterol acyltransferase deficiency: a clinicopathologic correlation. 61 54
19592052 2009
46
Forkhead box transcription factor O1 inhibits cholesterol 7alpha-hydroxylase in human hepatocytes and in high fat diet-fed mice. 54 61
19463968 2009
47
Functional variant disrupts insulin induction of USF1: mechanism for USF1-associated dyslipidemias. 61 54
20031629 2009
48
Adipokines and etiopathology of metabolic disorders. 61 54
19750255 2009
49
Metabolic consequences of peritoneal dialysis treatment. 61 54
19859052 2009
50
A unique rodent model of cardiometabolic risk associated with the metabolic syndrome and polycystic ovary syndrome. 61 54
19470707 2009

Variations for Lipid Metabolism Disorder

ClinVar genetic disease variations for Lipid Metabolism Disorder:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 APOE NM_000041.4(APOE):c.461G>T (p.Arg154Leu) SNV Likely pathogenic 375636 rs200703101 19:45412014-45412014 19:44908757-44908757

Expression for Lipid Metabolism Disorder

Search GEO for disease gene expression data for Lipid Metabolism Disorder.

Pathways for Lipid Metabolism Disorder

Pathways related to Lipid Metabolism Disorder according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.97 PPARG PPARA LPL LIPC INS HMGCR
2
Show member pathways
12.75 PPARG PPARA LPL LEP HMGCR FADS1
3
Show member pathways
12.58 LPL APOE APOC3 APOB APOA1
4 12.45 PPARG INS HNF4A APOE ADIPOQ
5
Show member pathways
12.39 PPARG LEP INS HNF4A HMGCR ADIPOQ
6
Show member pathways
12.39 LPL LIPC CETP APOE APOC3 APOB
7
Show member pathways
12.25 LPL APOE APOC3 APOB APOA1
8
Show member pathways
12.24 SERPINE1 INS CRP APOE APOB APOA1
10 11.78 PPARG LPL LEP INS ADIPOQ
11
Show member pathways
11.76 INS HNF4A ADIPOQ
12
Show member pathways
11.73 PPARG PPARA HNF4A
13 11.68 SERPINE1 RETN PPARG PPARA LPL LEP
14 11.66 PPARG LPL INS HMGCR
15 11.61 PPARA LEP ADIPOQ
16 11.58 PPARG PPARA LPL APOC3 APOA5 APOA1
17 11.57 SERPINE1 LEP HNF4A
18 11.39 INS HNF4A APOA1
19
Show member pathways
11.35 LPL LIPC HMGCR CETP APOE APOC3
20 11.12 PPARG LEP ADIPOQ
21 11.08 PPARA APOC3 APOA5 APOA1
22 11.05 PPARG LEP ADIPOQ

GO Terms for Lipid Metabolism Disorder

Cellular components related to Lipid Metabolism Disorder according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.2 SERPINE1 RETN LPL LIPC LEP INS
2 extracellular space GO:0005615 10.13 SERPINE1 RETN LPL LIPC LEP INS
3 collagen-containing extracellular matrix GO:0062023 9.91 SERPINE1 APOE APOC3 APOA1 ADIPOQ
4 endoplasmic reticulum lumen GO:0005788 9.91 LIPC INS APOE APOB APOA5 APOA1
5 early endosome GO:0005769 9.88 APOE APOC3 APOB APOA5 APOA1
6 low-density lipoprotein particle GO:0034362 9.71 APOE APOB APOA5 APOA1
7 intermediate-density lipoprotein particle GO:0034363 9.67 APOE APOC3 APOB APOA1
8 endocytic vesicle lumen GO:0071682 9.63 APOE APOB APOA1
9 high-density lipoprotein particle GO:0034364 9.63 LIPC CETP APOE APOB APOA5 APOA1
10 spherical high-density lipoprotein particle GO:0034366 9.52 APOC3 APOA1
11 discoidal high-density lipoprotein particle GO:0034365 9.49 APOE APOA1
12 very-low-density lipoprotein particle GO:0034361 9.43 LPL APOE APOC3 APOB APOA5 APOA1
13 chylomicron GO:0042627 9.1 LPL APOE APOC3 APOB APOA5 APOA1

Biological processes related to Lipid Metabolism Disorder according to GeneCards Suite gene sharing:

(show top 50) (show all 79)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 10.08 INS APOE APOB APOA5 APOA1
2 lipid transport GO:0006869 10.07 CETP APOE APOC3 APOB APOA5 APOA1
3 negative regulation of inflammatory response GO:0050728 10.05 PPARG PPARA APOE APOA1 ADIPOQ
4 steroid metabolic process GO:0008202 10.04 HMGCR CETP APOE APOB APOA1
5 glucose homeostasis GO:0042593 10.04 PPARG LEP INS HNF4A ADIPOQ
6 response to nutrient GO:0007584 10.03 PPARG LEP HMGCR FADS1 APOA1 ADIPOQ
7 lipid metabolic process GO:0006629 10.03 PPARG LPL LIPC LEP HNF4A HMGCR
8 fatty acid metabolic process GO:0006631 10.02 PPARG PPARA LPL FADS1
9 retinoid metabolic process GO:0001523 10 LPL APOE APOC3 APOB APOA1
10 cholesterol metabolic process GO:0008203 10 LIPC LEP HMGCR CETP APOE APOB
11 lipid catabolic process GO:0016042 9.99 LPL LIPC APOC3 APOB
12 response to ethanol GO:0045471 9.99 PPARA LEP HMGCR ADIPOQ
13 regulation of lipid metabolic process GO:0019216 9.98 PPARG PPARA HNF4A HMGCR FADS1 APOA5
14 response to insulin GO:0032868 9.97 RETN PPARA LEP FADS1
15 triglyceride metabolic process GO:0006641 9.97 LPL CETP APOE APOC3 APOA5
16 lipid homeostasis GO:0055088 9.96 PPARG HNF4A CETP APOE
17 intermembrane lipid transfer GO:0120009 9.95 CETP APOE APOB APOA1
18 response to organic substance GO:0010033 9.93 PPARG FADS1 APOB
19 circadian rhythm GO:0007623 9.93 SERPINE1 LEP ADIPOQ
20 triglyceride catabolic process GO:0019433 9.93 LPL LIPC APOC3 APOB APOA5
21 response to nutrient levels GO:0031667 9.92 LEP HMGCR ADIPOQ
22 cholesterol efflux GO:0033344 9.92 APOE APOC3 APOB APOA5 APOA1
23 response to glucose GO:0009749 9.91 LPL HNF4A ADIPOQ
24 fatty acid biosynthetic process GO:0006633 9.91 LPL LIPC FADS1
25 regulation of blood pressure GO:0008217 9.91 PPARG LEP ACE
26 cholesterol transport GO:0030301 9.91 LIPC CETP APOB APOA1
27 positive regulation of lipid biosynthetic process GO:0046889 9.91 PPARA INS APOE APOA5 APOA1
28 regulation of circadian rhythm GO:0042752 9.9 PPARG PPARA HNF4A
29 glucose metabolic process GO:0006006 9.9 LEP INS ADIPOQ
30 low-density lipoprotein particle remodeling GO:0034374 9.9 LIPC CETP APOE APOB
31 reverse cholesterol transport GO:0043691 9.89 LIPC CETP APOE APOC3 APOA1
32 negative regulation of MAP kinase activity GO:0043407 9.88 HMGCR APOE ADIPOQ
33 intracellular receptor signaling pathway GO:0030522 9.88 PPARG PPARA HNF4A
34 phospholipid efflux GO:0033700 9.88 APOE APOC3 APOA5 APOA1
35 chylomicron assembly GO:0034378 9.88 APOE APOC3 APOB APOA1
36 high-density lipoprotein particle remodeling GO:0034375 9.88 LIPC CETP APOE APOC3 APOA1
37 cholesterol biosynthetic process GO:0006695 9.87 HMGCR APOA5 APOA1
38 negative regulation of protein secretion GO:0050709 9.86 INS HMGCR APOE
39 positive regulation of cholesterol efflux GO:0010875 9.85 APOE APOA1 ADIPOQ
40 phosphatidylcholine metabolic process GO:0046470 9.85 CETP APOA5 APOA1
41 chylomicron remnant clearance GO:0034382 9.85 LIPC APOE APOC3 APOB
42 phospholipid homeostasis GO:0055091 9.84 HNF4A CETP APOA1
43 high-density lipoprotein particle assembly GO:0034380 9.84 APOE APOA5 APOA1
44 positive regulation of cholesterol esterification GO:0010873 9.82 APOE APOA5 APOA1
45 regulation of Cdc42 protein signal transduction GO:0032489 9.81 APOE APOC3 APOA1
46 positive regulation of fatty acid metabolic process GO:0045923 9.8 PPARG PPARA ADIPOQ
47 lipoprotein biosynthetic process GO:0042158 9.8 APOE APOB APOA1
48 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.8 PPARG PPARA CRP CETP ADIPOQ
49 lipoprotein metabolic process GO:0042157 9.8 PPARA APOE APOC3 APOB APOA5 APOA1
50 regulation of intestinal cholesterol absorption GO:0030300 9.79 LEP APOA5 APOA1

Molecular functions related to Lipid Metabolism Disorder according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 lipid binding GO:0008289 9.91 PPARA CETP APOE APOC3 APOA5 APOA1
2 heparin binding GO:0008201 9.85 LPL LIPC APOE APOB APOA5
3 hormone activity GO:0005179 9.78 RETN LEP INS ADIPOQ
4 nuclear receptor activity GO:0004879 9.73 PPARG PPARA HNF4A
5 phospholipid binding GO:0005543 9.72 APOE APOC3 APOB APOA5 APOA1
6 cholesterol binding GO:0015485 9.71 CETP APOC3 APOA5 APOA1
7 signaling receptor binding GO:0005102 9.7 SERPINE1 LPL LEP HNF4A APOE APOA1
8 phosphatidylcholine binding GO:0031210 9.69 CETP APOA5 APOA1
9 lipid transporter activity GO:0005319 9.67 APOE APOB APOA1
10 phospholipase A1 activity GO:0008970 9.6 LPL LIPC
11 phosphatidylserine 1-acylhydrolase activity GO:0052739 9.59 LPL LIPC
12 1-acyl-2-lysophosphatidylserine acylhydrolase activity GO:0052740 9.58 LPL LIPC
13 lipase inhibitor activity GO:0055102 9.58 APOC3 APOA1
14 lipase binding GO:0035473 9.57 APOB APOA5
15 lipoprotein lipase activity GO:0004465 9.55 LPL LIPC
16 triglyceride binding GO:0017129 9.54 LPL CETP
17 lipoprotein particle binding GO:0071813 9.54 LPL APOE APOA1
18 high-density lipoprotein particle receptor binding GO:0070653 9.52 APOC3 APOA1
19 phosphatidylcholine-sterol O-acyltransferase activator activity GO:0060228 9.43 APOE APOA5 APOA1
20 low-density lipoprotein particle receptor binding GO:0050750 9.26 CRP APOE APOB APOA5
21 intermembrane cholesterol transfer activity GO:0120020 8.92 CETP APOE APOB APOA1

Sources for Lipid Metabolism Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
12